Shared on 17 Jun 26

XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential

X4’s drug gets the green light in Europe for a very rare immune disorder, giving it a fresh path to reach patients outside the US with help from a commercial partner. Analysts also grow more optimistic that the same medicine could tap a much bigger patient group, but the company raises new funding along the way.

0 views

Shared on 04 May 26

XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential

Analysts have raised their price target on X4 Pharmaceuticals to $12, citing what they view as significant upside potential from mavorixafor as a key value driver for WHIM syndrome and primary chronic neutropenia, along with a current valuation that they see as not fully reflecting this opportunity. Analyst Commentary Recent Street research frames X4 Pharmaceuticals as a focused hematology company, with attention centered on mavorixafor as a potential first in class oral CXCR4 antagonist for WHIM syndrome and primary chronic neutropenia.

3 views

Shared on 20 Apr 26

XFOR: CXCR4 Program In WHIM And Chronic Neutropenia Will Drive Future Upside

Analysts have reset their price target on X4 Pharmaceuticals to $12, citing Guggenheim's recent initiation, which highlights mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary The latest Street research frames X4 Pharmaceuticals as closely tied to the success of mavorixafor in WHIM syndrome and primary chronic neutropenia.

1 view

Shared on 05 Apr 26

Fair value Increased 100%

XFOR: Mavorixafor Franchise Is Expected To Drive Future Upside Potential

Narrative Update Analysts have raised their price target for X4 Pharmaceuticals to $12, citing the perceived upside in mavorixafor as a key value driver and updating fair value assumptions to $10.00, along with adjusted growth, margin, discount rate, and future P/E inputs. Analyst Commentary Recent research points to mavorixafor as the central piece of the X4 Pharmaceuticals story, with coverage initiating at a $12 price target that aligns with the view of the drug as a key value driver.

1 view

Shared on 21 Feb 26

Fair value Increased 25%

XFOR: Higher Fair Value Will Reflect Stronger Outlook Despite Margin Headwinds

Analysts have lifted their fair value estimate for X4 Pharmaceuticals from $4.00 to $5.00 per share, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the new price target. Valuation Changes Fair Value was raised from $4.00 to $5.00 per share, an increase of 25% in the modelled estimate.

2 views

Shared on 06 Feb 26

XFOR: Fair Value View Will Balance Dilution Concerns And Execution Milestones

Analysts have lifted their price target on X4 Pharmaceuticals to $4.00 per share from $4.00, citing updated assumptions around revenue growth, discount rate, profit margin, and future P/E that are now reflected in their models. Valuation Changes Fair Value: Maintained at $4.00 per share, with no change from the prior estimate.

3 views

Shared on 23 Jan 26

XFOR: Future Outlook Weighs October Financing Dilution Against Execution And Earnings Milestones

Narrative Update Analysts have trimmed their 12 month price target on X4 Pharmaceuticals to US$7.50 from US$9.00, mainly reflecting updated financing assumptions after the recent earnings report and the October capital raise. Analyst Commentary Bearish analysts are using the latest earnings report and the October capital raise to reset expectations on X4 Pharmaceuticals, with the 12 month price target update to US$7.50 at the center of their view.

4 views

Shared on 09 Jan 26

XFOR: Future Outlook Balances October Financing Dilution With Execution And Earnings Milestones

Analysts have trimmed their 12 month price target for X4 Pharmaceuticals to US$7.50 from US$9.00, citing updated financing assumptions following the October capital raise as well as recent earnings and corporate updates. Analyst Commentary Bearish analysts are framing the lower US$7.50 12 month price target as a reset that reflects updated expectations after recent earnings and the October capital raise.

4 views

Shared on 22 Dec 25

Fair value Increased 14%

XFOR Future Outlook Weighs Financing Dilution Against Long Term Commercial Upside

Analysts have trimmed their price target on X4 Pharmaceuticals by $1.50 to $7.50, citing updated models that factor in revised financing assumptions following the company’s recent earnings report and October capital raise. Analyst Commentary Bearish analysts have pointed to the latest target cut as evidence that X4 Pharmaceuticals faces a more challenging path to value creation than previously modeled, with revised financing assumptions weighing on upside potential.

4 views

Intensifying Trial Risks Will Hobble Returns Yet Open Global Potential

XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential

XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential

XFOR: CXCR4 Program In WHIM And Chronic Neutropenia Will Drive Future Upside

XFOR: Mavorixafor Franchise Is Expected To Drive Future Upside Potential

XFOR: Higher Fair Value Will Reflect Stronger Outlook Despite Margin Headwinds

XFOR: Fair Value View Will Balance Dilution Concerns And Execution Milestones

XFOR: Future Outlook Weighs October Financing Dilution Against Execution And Earnings Milestones

XFOR: Future Outlook Balances October Financing Dilution With Execution And Earnings Milestones

XFOR Future Outlook Weighs Financing Dilution Against Long Term Commercial Upside

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on X4 Pharmaceuticals

Company analysis

CEO & management